Pan-RAS inhibitor ADCs emerge at AACR 2026

Pan-RAS inhibition is producing unprecedented survival gains in pancreatic cancer and other RAS-mutant tumors, but systemic toxicity remains a major constraint. At AACR, at least four companies proposed a solution: conjugating pan-RAS inhibitors to tumor-targeting antibodies to concentrate activity in tumors and reduce off-tumor adverse events.

In the 2026 American Association for Cancer Research (AACR) annual meeting abstracts, BioCentury identified seven presentations from four biotech companies describing antibody-drug conjugates (ADCs) designed to deliver pan-RAS inhibitors...